CNS Pharmaceuticals, an early stage biotech developing therapies for brain cancer and other CNS tumors, announced terms for its IPO on Friday.
The Houston , TX-based company plans to raise $10 million by offering 2.1 million shares at a price range of $4 to $5. At the midpoint of the proposed range, CNS Pharmaceuticals would command a fully diluted market value of $77 million.
CNS Pharmaceuticals was founded in 2017 and plans to list on the Nasdaq under the symbol CNSP. The Benchmark Company is the sole bookrunner on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.